# Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis

> **NCT02132260** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 890 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** Naftifine Hydrochloride Cream 2%
- **DRUG:** Naftin® (Naftifine Hydrochloride) Cream 2%
- **DRUG:** Placebo Topical Cream

## Key facts

- **NCT ID:** NCT02132260
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 890 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132260, "Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02132260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*